Publicacions en què col·labora amb Maria Angeles Muñoz Fernandez (22)

2024

  1. Low unspliced cell-associated HIV RNA in early treated adolescents living with HIV on long suppressive ART

    Frontiers in Immunology, Vol. 15

2023

  1. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

    The Lancet Child and Adolescent Health, Vol. 7, Núm. 10, pp. 718-727

  2. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

    eClinicalMedicine, Vol. 60

2022

  1. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 9, pp. e627-e637

  2. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

    The Lancet HIV, Vol. 9, Núm. 9, pp. e638-e648

2019

  1. Prognostic factors of a lower CD4/CD8 ratio in long term viral suppression HIV infected children

    PLoS ONE, Vol. 14, Núm. 8

  2. Reduced Time to Suppression among Neonates with HIV Initiating Antiretroviral Therapy Within 7 Days after Birth

    Journal of Acquired Immune Deficiency Syndromes, Vol. 82, Núm. 5, pp. 483-490

  3. Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015

    PLoS ONE, Vol. 14, Núm. 10

2018

  1. Early and highly suppressive antiretroviral therapy are main factors associated with low viral reservoir in European perinatally HIV-infected children

    Journal of Acquired Immune Deficiency Syndromes

  2. Sleep Profile and Self-Reported Neuropsychiatric Symptoms in Vertically HIV-Infected Adolescents on cART

    Journal of Pediatric Infectious Diseases, Vol. 13, Núm. 4, pp. 300-307

2017

  1. Low Bone Mineral Density in Vertically HIV-infected Children and Adolescents: Risk Factors and the Role of T-cell Activation and Senescence

    Pediatric Infectious Disease Journal

2016

  1. Disease disclosure, treatment adherence, and behavioural profile in a cohort of vertically acquired HIV-infected adolescents. NeuroCoRISpeS study

    AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, Vol. 28, Núm. 1, pp. 124-130

2015

  1. Early antiretroviral therapy in children perinatally infected with HIV: A unique opportunity to implement immunotherapeutic approaches to prolong viral remission

    The Lancet Infectious Diseases, Vol. 15, Núm. 9, pp. 1108-1114

  2. Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early Antiretroviral Therapy

    Clinical Infectious Diseases, Vol. 61, Núm. 7, pp. 1169-1178

  3. Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults

    BMC Infectious Diseases, Vol. 15, Núm. 1

2014

  1. Cardiovascular biomarkers in vertically HIV-infected children without metabolic abnormalities

    Atherosclerosis, Vol. 233, Núm. 2, pp. 410-414

  2. Functionally defective high-density lipoproteins are related to heightened T-cell activation in vertically HIV-infected adolescents

    Journal of Acquired Immune Deficiency Syndromes, Vol. 66, Núm. 3, pp. 265-269

  3. Subclinical atherosclerosis and markers of immune activation in hiv-infected children and adolescents: The carovih study

    Journal of Acquired Immune Deficiency Syndromes, Vol. 65, Núm. 1, pp. 42-49

2011

  1. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 10, pp. 2362-2371

  2. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: An open-label, randomised phase 2/3 trial

    The Lancet Infectious Diseases, Vol. 11, Núm. 4, pp. 273-283